肿瘤细胞治疗研究
英文原题：Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.
CAR-T 细胞疗法已彻底改变了血液系统恶性肿瘤患者的治疗结局，包括 B 细胞急性淋巴细胞白血病（B-ALL）、弥漫大 B 细胞淋巴瘤（DLBCL）和多发性骨髓瘤（MM）。
CAR-T 细胞疗法彻底改变了血液系统恶性肿瘤患者的治疗结局，包括B细胞急性淋巴细胞白血病（B-ALL）、弥漫大B细胞淋巴瘤（DLBCL）和多发性骨髓瘤（MM）。然而，抗原逃逸、T细胞耗竭，以及CAR-T细胞在急性髓系白血病（AML）和T细胞白血病中的疗效有限等问题仍然存在。本综述旨在总结自2015年以来的人体试验和研究成果，重点关注最近两年的创新进展。我们讨论克服耐药的策略，包括多靶点CAR、下一代构建体以及治疗耐药癌症的联合策略；也探讨提高安全性和可及性的方法，包括异基因CAR-T方案。本文提出，可利用CRISPR增强型CAR及基于合成生物学的异基因系统提升CAR-T疗效和可及性，推动肿瘤学迈向持久治愈。
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment outcomes of patients with hematologic malignancies, including B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM). However, issues such as antigen escape, T-cell exhaustion, and the limited efficacy of CAR-T cells in acute myeloid leukemia (AML) and T-cell leukemias still persist. This review aims to summarize human trials and achievements from 2015 with a focus on the innovations within the last two years. We discuss strategies to overcome resistance, including multi-target CARs, next-generation constructs, and combination strategies to treat resistant cancers. We also explore the ways to increase safety and access, including allogeneic CAR-T options. In this article, we propose CRISPR-enhanced CARs and synthetic biology-based allogeneic systems to enhance the efficacy and accessibility of CAR-T therapy with the aim of moving the field of oncology towards durable cures.
MEMBER ACCOUNT
登录成功会直接打开下一页。
